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Abstract.  Receptor-bound urokinase-type plasminogen 
activator (uPA) remains associated to the surface of 
human monocytes for many hours.  Monocytes induced 
to migrate in a chemotactic gradient of f-Met-Leu-Phe 
rapidly polarize their uPA receptors to the leading 
front of the cells. Receptor-bound enzyme can be in- 
hibited by plasminogen activator inhibitor 2  (PAI-2), 
with a  kinetics comparable to that determined for the 
free enzyme, and uPA/PAI-2 complexes can bind to 
the uPA receptor.  In contrast to the active enzyme, the 
uPA/PAI-2 complex is rapidly cleared from the mono- 
cyte cell surface; this involves an initial cleavage of 
the complex at the cell surface, followed by endocyto- 
sis and degradation. These results indicate that the 
uPA receptor can function both to focus plasmin- 
mediated extracellular matrix degradation in front of 
migrating cells, and to target uPA/PAI-2 enzyme/inhib- 
itor complexes for degradation; they suggest that this 
receptor is a  key determinant in the control of uPA- 
catalyzed extracellular proteolysis. 
T 
HE migration of cells within tissues and between dif- 
ferent body  compartments  requires  the  proteolytic 
degradation of components of extracellular matrices. 
Through the generation of plasmin and in conjunction with 
other enzymes such as collagenases and elastases, plasmino- 
gen activators (PAs)  ~ can catalyze the degradation of most 
proteins of the extracellular space (Bogenmann and Jones, 
1983;  Heisel  et  al.,  1983;  Bergman  et  al.,  1986).  The 
urokinase-type PA (uPA) is produced by a variety of migra- 
tory cells, including invasive malignant cells (Dane et al., 
1985),  implanting  trophoblastic  cells  (Strickland  et  al., 
1976; Sappino et al., 1989),  monocytes-macrophages (Vas- 
salli et al., 1984),  capillary endothelial cells (Pepper et al., 
1987), and inhibition of uPA activity prevents cell migration 
in  different experimental  systems  (Ossowski  and  Reich, 
1983;  Mignatti et al.,  1986;  Ossowski,  1988a). 
A number of cell types express on their surface a binding 
site for uPA and its single-chain zymogen prouPA (Bajpai 
and Baker, 1985; Stoppelli et al., 1985, 1986; Vassalli et al., 
1985; Cubellis et al., 1986; Blasi et al., 1987). This receptor 
has recently been characterized; it behaves as an integral 
membrane protein (Estreicher et al.,  1989),  and comprises 
at least one carbohydrate-containing polypeptide chain of 
55,000  Mr (Nielsen et al.,  1988).  Binding occurs through 
the noncatalytic A chain of the two-chain enzyme (Stoppelli 
1. Abbreviations  used in this paper: fMLP, N-formyl-L-methionyl-L-leucyl- 
phenylalanine; DFP, diisopropylfluorophosphate;  PA, plasminogen activa- 
tor; PAI, PA inhibitor; uPA, urokinase type PA. 
et al., 1985; Vassalli et al., 1985), and involves the "growth 
factor-like" domain of the molecule (Appella et al.,  1987). 
The bound zymogen can be cleaved by plasmin into the two- 
chain enzyme (Cubellis et al., 1986), and the bound enzyme 
is catalytically active (Vassalli et al.,  1985).  The source of 
the enzyme that binds to this receptor may differ for different 
cell types. In certain cases, the enzyme appears to be synthe- 
sized by the receptor-bearing cells themselves, and to bind 
in an autocrine way after secretion (Stoppelli et al., 1986). 
Alternatively, cells that do not produce uPA will bind enzyme 
synthesized by a  different cell type (Huarte et al.,  1987). 
Also, prouPA is present in the blood plasma (Tissot et al., 
1982;  Wun et al.,  1982),  at a concentration (ml0  -~0 M) in 
the range of the Kd of its interaction with the receptor, and 
could bind to receptor-bearing circulating cells. Thus, while 
uPA is a secreted protein, its subsequent binding to a high 
affinity cell surface receptor can localize the enzyme to the 
plasma membrane. The expression of the uPA receptor ap- 
pears to be a versatile and widespread mechanism to limit 
the activity of the uPA-plasmin  system to the close environ- 
ment of the cell. 
In many cases, however, ligand-plasma membrane recep- 
tor interactions lead to rapid internalization of the ligand; if 
uPA functions as an ectoenzyme, it should not be removed 
rapidly  after  binding  to  the  plasma  membrane.  Also, 
directed cell migration requires localized proteolysis, and 
polarized expression of the uPA receptor could be a way to 
focus plasmin-mediated extracellular matrix degradation to 
the leading edge of  migrating cells. Finally, three serpin class 
© The Rockefeller University Press, 0021-9525/90/08/783/10  $2.00 
The Journal of Cell Biology, Volume 111, August 1990 783-792  783 antiproteases with high affinity towards secreted uPA have 
been identified. While it has been suggested that membrane- 
associated uPA might be protected from inhibition by these 
serpins (Chapman et al., 1982; Blasi et al., 1987), recent in- 
vestigations have shown that plasminogen activator inhibi- 
tors (PAls) can react with receptor-bound uPA (Cubellis et 
al.,  1989; Kirchheimer and Remold, 1989);  thus, it is also 
possible that the uPA receptor could function to favor the 
clearance and degradation of uPA/inhibitor complexes. The 
experiments reported here were designed to address these is- 
sues. To this effect, we have used human monocytes, as well 
as ceils from two human monocytic lines, U937 and THP-1. 
The uPA receptor of U937 cells has been extensively charac- 
terized (Stoppelli et al., 1985; Vassalli et al., 1985; Nielsen 
et al., 1988), and THP-1 cells (Tsuchiya et al., 1980), while 
bearing uPA receptors that are indistinguishable from those 
of monocytes and U937 cells, produce essentially no detect- 
able PAIs. The results obtained help better define the proba- 
ble physiological roles of the uPA receptor: to focus uPA- 
catalyzed generation  of plasmin  to  the  leading  front of 
migrating ceils, and to target uPA/inhibitor complexes for 
degradation. 
Materials and Methods 
Cell Culture 
Human  peripheral  blood  mononuclear  cells  were  prepared  by  Ficoll- 
Hypaque  sedimentation, and  cultured  for 20  h  in  RPMI  1640  (Gibco 
Laboratories,  Grand  Island,  NY)  supplemented with  10%  FBS  (Gibco 
Laboratories) that had been heated to 560C for 30 min (HI-FBS) in 35-mm 
tissue culture Petri dishes (Vassalli et al.,  1985). 
U937 cells were grown as described (Vassalli et al., 1985).  THP-1 ceils 
(Tsuchiya  et al.,  1980) were a kind gift from Dr. Jean-Michel Dayer; they 
were grown in RPMI  1640 medium (Gibco Laboratories) supplemented 
with 25-raM Hepes; 110 U/ml penicillin (Pfitzer, Zurich, Switzerland); 110 
/zg/rnl  streptomycin (Gruenenthal,  Bern,  Switzerland);  and  10%  FBS. 
U937 and THP-1  cells were collected by centrifugation (10 min, 300 g), 
washed, and resuspended in RPMI 1640  1 mg/mi acid-treated BSA (RPMI- 
BSA; No.  81-001; Miles Laboratories, Inc., Naperville, IL) (Loskutoff, 
1978). 
Iodination of uPA 
55,000 and 33,000 Mr two-chain human uPA were obtained from Serono 
(Denens, Switzerland). Concentrations of the enzymes were determined by 
active site titration (Chase and Shaw,  1967).  uPA was radiolabeled using 
iodogen (Pierce Chemical Co., Rockford, IL) and Na-125I (Amersham In- 
ternational, Amersham, England), as described (Vassalli et al.,  1984) and 
was used within a month. 125I-uPA had a specific activity of 1 -  5  x  107 
cpm/~tg  and was at least 90%  enzymatically active. 
Electron Microscopy 
Adherent monocytes were washed three times with RPMI  1640,  and in- 
cubated at 37°C for different time periods in RPMI 1640 containing 25 mM 
Hepes,  1  mg/ml  BSA,  and  1.6  ×  10  -9  M  diisopropylfluorophosphate 
(DFP)-inactivated 55,000 Mr t25I-uPA (Vassalli  et al.,  1985).  After exten- 
sive washing with ice cold PBS containing 1 mg/ml BSA, the cells were 
fixed with 2.5%  glutaraldehyde in 0.I-M cacodylate buffer (pH 7.4),  col- 
lected by scraping with a rubber policeman, dehydrated, and processed for 
autoradiography and electron microscopy as described (Carpentier et al., 
1978). 
U937 cells were cultured at 370C for different time periods in presence 
of 1.6 ×  10  -9 M DFP-inactivated 55,000 Mr t25I-uPA, washed three times 
with RPMI-BSA, and cell-associated radioactivity was determined. Non- 
specific  binding was determined in presence of a 30-fold excess of nonradio- 
active ligand, and never exceeded 5 % of total binding. The cells were then 
fixed in 2.5%  glutaraldehyde in 0.1 M  cacodylate buffer (pH 7.4),  dehy- 
drated and processed for quantitative EM autoradiography as described 
(Carpentier et al., 1978).  The analysis of the autoradiographic data as well 
as the morphometric quantitation were performed as previously described 
(Carpentier et al., 1979, 1981), and considering that a grain was associated 
with the plasma membrane when its center was within 250 nm of this struc- 
ture. A background value of 10%  was subtracted from the "internalized" 
fraction (Carpentier et al.,  1978).  Binding of 12sI-insulin to U937 cells, 
preparation of the samples and analysis of the data were performed as de- 
scribed (Robert et al.,  1984). 
Chemotaxis 
Human monocytes were prepared as described above; U937 cells were al- 
lowed to auach to the bottom of 35-mm tissue culture Petri dishes by cultur- 
ing for 24 h in presence of 50 ng/ml PMA. After washing with RPMI-BSA, 
some of the culture dishes were divided into tv~ concentric chambers: 
medium was removed and a high vacuum grease-coated 10-mm Teflon ring 
was fixed to the center of the dish; a glass capillary tube (4-ram long with 
a 0.l-ram opening) was placed in the grease, below the Teflon ring, so as 
to connect the tv~ chambers. Culture medium was added to the two cham- 
bers (inner, 100/~1; outer, 2.5 ml); when Niagara blue (0.04%) was added 
to the outer chamber of such culture vessels, dye could be seen to have 
diffused  to  "~25%  of  the  inner  chamber  after  15  min.  N-formyl-L- 
methionyl-L-leucyl-L-phcnylalanine (fMLP;  Sigma  Chemical  Co.,  St. 
Louis, MO) (25 #1 of a  10  -3 M solution) was added to the outer chamber, 
close to the opening of the capillary tube (Fig. 3, B and E). For control cul- 
tures (Fig. 3, A and D) and cultures exposed to a uniform concentration of 
fMLP (C and F), the Petri dishes were not divided in two chambers; where 
appropriate (C and F), fMLP was added to a final concentration of 10  -5 M. 
After 15 rain at 37°C, the cells were washed with ice cold PBS-BSA. DFP- 
inactivated 55,000 Mr  t25I-uPA (1.6  ×  10  --9 M  in PBS-BSA) was added, 
and allowed to bind for 30 min at 4°C. The cells were then washed four 
times with cold PBS-BSA, and fixed for 30 rain at room temperature with 
2 % glutaraldehyde in 0.1 M cacodylat¢ buffer (pH 7.6); before dismounting 
the partition between the two chambers, the position of the capillary tube 
was recorded. Petri dishes were processed for autoradiography, and exam- 
ined in a Zeiss Axiophot. The proportion of polarized cells was determined 
by counting 200-600 cells per experimental condition. Experiments were 
performed four times for both cell types, with similar results. 
SDS-PAGE and Autoradiography 
Samples were electrophoresed in the presence of SDS under nonreducing 
conditions in 10% polyacrylamide gels using the buffer system of Laemmli 
(1970).  Molecular weights were calculated from the position of marker pro- 
reins (low molecular weight calibration kit; Pharmacia Fine Chemicals, Pis- 
cataway, NJ) electrophoresed in parallel lanes and stained with Coomassie 
brilliant blue R250. 
Autoradiography of the gels was performed as described (Vassalli et al., 
1984). 
PAI-2 (PAl Type 2) 
PAI-2, purified as described (Kruithof et al., 1986),  was a kind gift of Dr. 
E. K. O.  Kruithof. 
Preparation of  Preformed Complexes 
33,000- and 55,000-Mr  12~I-uPA (10  -s M), purified by gel filtration on an 
Utrogel  Ac.A 54  column  in  0.5  M  NaC1,  8  mM  Na2HPO4,  1.5  mM 
KH2PO4,  were incubated in the presence of purified PAI-2 (5  ×  10  -7 M) 
for 2 h at 4°C. Quantitative formation of complexes was assessed by SDS- 
PAGE followed by autoradiography of the gel. 
Single Cell Plaque Assay 
THP-1 cells were preincubated in the absence or in the presence of either 
uPA or purified prouPA (2  x  10  -9 M). Purified prouPA was a kind gift of 
Dr. W.-D. Schleuning. After 1 h at 4°C, the cells were washed and further 
incubated at 4°C in the presence or the absence of PAI-2  (2  ×  l0  -s M). 
After washing, aliquots of 5  ×  103 cells of each condition were resus- 
pcnded in a mixture of 1.3% casein, 0.8% agar and 40/~g/ml plasminogen 
in RPMI  1640 medium, and, where indicated, 2  ×  10  -s M  PAI-2  and 
plated in 35-mm tissue culture dishes (Falcon Labware, Oxuard, CA). Pho- 
tographs were taken under dark ground illumination. 
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of DFP-inactivated 125I-uPA; seen at 11,000×. Bar, 1 #m. (B) Upper: quantitative analysis by high resolution EM autoradiography of the 
distribution of DFP-inactivated 125I-uPA  in U937 cells after different times of culture at 37°C in presence of the ligand. (B) Lower: same 
as upper, but for ~25I-insulin. 
Interaction of  Bound uPA with PAI-2 
THP-I cells (107jml) were preincubated with 5  x  10  -9 M  12SI-uPA for 2 h 
at 4°C. After extensive washings, the cells were incubated in the absence 
or presence of 2  x  10  -g M PAI-2 at 4°C or 37°C as indicated. At the end 
of  the incubations, the cells were applied onto a 250 t~l oil cushion consist- 
ing of  a 6:4 mixture (vol/vol) of  dioctylphtalate (No. 821874;  Merck A. G., 
Darmstadt, FRG) and dibutylphtalate (No. 800919; Merck) in polyethylene 
microfuge tubes (Milian Instruments S. A., Geneva, Switzerland); and cen- 
trifuged at 4°C for 30 s at 12,000 g; the closed tubes were cut and the radio- 
activity in cell pellets and supernatants counted (Celada et al., 1984).  The 
cells were solubilized in 0.2% Triton X-100. Nuclei were removed by cen- 
trifugation (10 rain, 800 g). Cells and supernatants were mixed with double 
strength electrophoresis sample buffer and analyzed by SDS-PAGE and au- 
toradiography of the gel  s. 
For experiments invoIving tryptic digestion of  cell surface-bound ligand, 
the samples were handled as above, except that before applying on the oil 
cushion the cells were centrifuged (10 min at 300 g), resuspended in PBS 
(107 cells/ml), and  incubated in the absence or in  the presence of L-1- 
tosylamido-2-phenylethyl  chloromethyl ketone (TPCK)-treated bovine pan- 
creatic trypsin (5  x  10  -7 M) for 10 min at 20°C; trypsin was inactivated 
by the addition of FBS (15%). 
Results 
Receptor-bound uPA Remains on the Cell Surface 
We  have  localized  125I-uPA by  EM  autoradiography  at 
different times after its addition to cultured human mono- 
cytes and  monocyte-like U937  cells.  For both cell types, 
most autoradiographic grains were found in the vicinity of 
the plasma membrane at all times studied.  Fig.  1 A is one 
of a series of pictures of monocytes that were used for quan- 
titative analysis: after 4 h of incubation at 37°C, 79% of the 
radiolabel was associated with the plasma membrane (+ 250 
nm). A similar analysis performed with U937 cells confirmed 
that receptor-bound ~2~I-uPA remains mostly associated with 
the plasma membrane of these cells also (Fig. 1 B). By con- 
trast, another cell surface receptor ligand, insulin, was rap- 
idly internalized in monocytes (Grunberger et al., 1985) and 
in U937 cells (Fig.  1 B). 
The  rate  of  disappearance  of  receptor-bound  12SI-uPA 
from the surface of U937 cells (by internalization and/or dis- 
sociation) was also determined (Fig. 2). After 5 h of incuba- 
tion at 37°C, two-thirds of the radiolabel that remained as- 
sociated with the cells could be removed by trypsin, a result 
consistent with previous reports by StoppeUi et al.  (1985) 
and Bajpai and Baker (1985).  Overall, the amount of cell 
surface-associated  ~2~I-uPA decreased  with  a  half-time  of 
,o5 h.  Our results are compatible with the idea that a role 
for the uPA receptor is to localize the (pro)enzyme to the cell 
surface, thus endowing the cell with a potent mechanism to 
generate plasmin-mediated proteolysis in its immediate envi- 
ronment. 
The uPA Receptor Is Polarized to the Leading Front 
of  Migrating Cells 
Nonuniform distribution of the uPA receptor could be a way 
to achieve polarization of  protease expression to discrete do- 
mains of the cell surface. To explore this, we determined the 
distribution  of receptor-bound  12~I-uPA, paying  particular 
attention to its possible association with surface projections. 
No preferential association was observed in the case of U937 
cells;  for monocytes,  however,  ~2SI-uPA was  found to  be 
more frequently associated with villous surface projections 
(73 %, 500 grains counted) than expected on the basis of the 
percent of the total cell surface contributed by these struc- 
tures  (57%)  (see Fig.  1, A).  Thus,  at least in the case of 
freshly prepared human monocytes, surface distribution of 
the uPA receptor on "resting" cells is not entirely random. 
Migration of monocytes can be triggered in response to 
chemotactic agents (Gallin and Quie, 1978). U937 cells and 
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Figure 2.  Fate  of receptor- 
bound I~I-uPA on U937 cells. 
Binding  of  DFP-inactivated 
55,000 Mr  125I-uPA (l.6-nM) 
to U937 cells was carried out 
for 1 h at 37°C, as described 
(VassaUi et al.,  1985). After 
washing by centrifugation in 
RPMI-BSA to remove free li- 
gand, the cells were incubated 
at 37°C. At various times, cul- 
tures were treated for 20 min at 37°C in presence or absence of 
trypsin (10 #g/ml), before washing and counting the cell-associated 
radioactivity. The results of two different experiments (o, x) are il- 
lustrated; each point represents the mean of duplicate cultures. 
monocytes attached to tissue culture plates were exposed for 
15 min to a concentration gradient of the chemotactic pep- 
tide fMLP. The uPA receptor was then localized by binding 
of  125I-uPA and  autoradiography  (Fig.  3).  For  both  cell 
types, some 30% of the cells expressed a highly asymmetric 
distribution of the receptor in response to the chemotactic 
signal; the radioactively labeled pole was always the leading 
edge of  the cell; i.e., that facing the source of  the chemotactic 
gradient. In the case of monocytes, the labeling was most in- 
tense on the cytoplasmic projections that were present at the 
leading edge, while U937 cells showed a uniform intense 
labeling of the leading edge. Polarized expression of the uPA 
receptor was a response to the chemotactic gradient, since 
a uniform concentration of fMLP did not increase the pro- 
portion of polarized cells above that observed in absence of 
the peptide. 
Receptor-bound uPA Can Be Inactivated by PAI-2 
The experiments reported above were performed using DFP- 
inactivated  125I-uPA to  avoid  reaction  of the  ligand  with 
PAI-2, which is synthesized and released by monocytes and 
U937 cells (Wohlwend et al.,  1987). To explore the fate of 
receptor-bound active uPA as well as that of its single-chain 
zymogen  prouPA,  we  used  a  different  cell  line  of the 
mononuclear phagocyte lineage, THP-1; THP-1 cells express 
uPA receptors that are indistinguishable from those of un- 
stimulated monocytes and U937 cells, but they do not pro- 
duce high levels of a PAl (data not shown, and see below 
Figs.  8 and 9). 
To investigate the  susceptibility of receptor-bound uPA 
and prouPA to inhibition by PAI-2, we first used a catalytic 
plaque assay, which reveals the activity of the cell-associated 
enzyme (Vassalli  et al.,  1985).  After incubation with  or 
without uPA or prouPA, THP-1 cells were cultured for 1 h 
at 4°C  in the presence or absence of PAI-2,  and washed. 
They were then embedded in substrate, and the formation of 
proteolytic plaques  was  observed  (Fig.  4,  A).  Only  few 
plaques developed when the ceils had not been incubated 
with uPA or prouPA,  indicating that THP-1  cells produce 
only low levels of the enzyme. After incubation with uPA, 
most cells were surrounded by a lytic zone; incubation of 
these cells in the presence of PAI-2 prevented the subsequent 
uPA-dependent  proteolytic activity.  Incubation  of THP-1 
cells with prouPA also resulted in the expression of proteo- 
lytic activity around the cells; in this case, however, PAI-2 
caused only a slight decrease in prouPA-dependent proteoly- 
sis.  Finally, addition of PAI-2 to the substrate in all cases 
prevented the formation of proteolytic plaques (Fig. 4, B). 
We interpret these observations as  follows.  (a)  Receptor- 
bound uPA is inhibited in the presence of PAI-2, indicating 
that binding to the receptor does not protect the enzyme from 
this inhibitor.  (b) Binding to the receptor does not render 
prouPA susceptible to reaction with PAI-2. The slight inhibi- 
tory effect of  PAI-2 may be because of activation of a fraction 
of the proenzyme during its binding or during incubation in 
the presence of PAI-2; alternatively, some PAI-2 may remain 
bound to the cells, and thus could react with uPA formed dur- 
ing  the  proteolytic assay.  (c)  The  formation  of plaques 
around prouPA-bearing ceils requires the conversion of the 
proenzyme to active uPA during  the catalytic assay (per- 
formed  in  the  presence  of plasminogen  containing  trace 
amounts of  plasmin), and this accounts for the effect of PAI-2 
when the inhibitor is present in the substrate used for the 
assay. 
The inhibition of soluble and receptor-bound uPA by PAI-2 
was compared by taking advantage of the formation of cova- 
lent complexes between the enzyme and the inhibitor; these 
complexes can be resolved from unreacted enzyme by SDS- 
PAGE, and their abundance provides a quantitative estimate 
of  the proportion of  enzyme that has reacted with PAI-2 (Fig. 
5). At the enzyme and inhibitor concentrations used in this 
experiment, half of the soluble (unbound) 55,000 Mr 1251- 
uPA had reacted with PAI-2 to form a 95,000-M, complex 
after a 10-15 min incubation at 4°C; a similar rate of  reaction 
was found for 33,000 Mr 12SI-uPA, which contaminates our 
uPA  preparation,  and  which  forms  a  73,000-Mr  complex 
with PAI-2.  The rate of inhibition of receptor-bound ~25I- 
uPA was slightly slower: half of the bound 55,000 Mr 12sI- 
uPA had reacted with PAI-2 to form the 95,000-Mr complex 
after '~40  min.  However, this  different kinetics  may  not 
necessarily reflect a  partial protection of the enzyme but 
could be due to the immobilization of uPA at the cell surface, 
whereas in solution both enzyme and inhibitor can diffuse 
freely.  Interestingly,  a  70,000-Mr  radioactive species  was 
observed at late times of incubation of receptor-bound '251- 
uPA with PAI-2; the significance of this species will be dis- 
cussed below. We conclude from this experiment that the in- 
hibition of receptor-bound uPA by PAI-2 is slightly slower 
than that of the soluble enzyme; however, the receptor does 
not shield the enzyme from the inhibitor. 
Since PA[-2 reacts only with catalytically active uPA, inhi- 
bition of receptor-bound uPA by PAI-2 provided a quantita- 
tive means to demonstrate that the enzyme remains function- 
ally active at the cell surface even after prolonged incubation 
at 37°C. THP-1 cells with receptor-bound ~25I-uPA were ex- 
posed to PAI-2  at various times up to 4 h after binding of 
the enzyme. At all times the majority of intact ~25I-uPA was 
able to react with PAI-2,  to form the covalent 95,000-Mr 
complex (Fig. 6). 
uPA/PAI-2 Complexes Are Cleared from the 
Cell Surface 
The lasting presence of receptor-bound uPA at the cell sur- 
face together with the ability of the enzyme to interact with 
PAI-2  suggests that the cell surface could remain encum- 
bered with uPA/PAI-2 complexes for several hours. An alter- 
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Figure 3. Polarized distribution  of 
the uPA receptor on U937 cells 
(left) and human monocytes (right) 
in a gradient of the chemotactic 
peptide fMLP. To localize the uPA 
receptor, ceils were incubated for 
30 min at 4°C in the presence of 
DFP-inactivated  55,000-M,  1251- 
uPA, washed, fixed and processed 
for autoradiography.  The autora- 
diographic grains (dark spots) are 
present throughout the cell periph- 
ery in A, C, D, and F, and are re- 
stricted to one side of the cells in 
B and E. (A and D) no fMLP (con- 
trol); (B and E) two polarized cells 
in a gradient of fMLP; the source 
of the gradient is at the top;  (C 
and F) fMLP,  no gradient.  Bar, 
10 gm.  (G)  Proportion of cells 
showing  a  polarized  binding  of 
125I-uPA in cultures A, B,  C, D, 
E, and F  (mean  +  SEM). 
nate possibility is that the fate of receptor-bound active uPA 
differs  from  that  of the  PAI-2-inhibited  enzyme.  To  dis- 
criminate between these  hypotheses,  THP-1  cells  were in- 
cubated with  125I-labeled prouPA,  uPA, or DFP-inactivated 
uPA, washed, and further incubated at 37°C in the presence 
or  in  the  absence  of PAI-2;  the  rate  of decrease  in  cell- 
associated radioactivity was comparable for prouPA, DFP- 
inactivated uPA and active uPA (Fig.  7).  Addition of PAI-2 
to cells that had been incubated with active tUI-uPA resulted 
in a  significantly faster loss in cell-associated radioactivity 
(Fig. 7); this appeared to require an interaction of PAI-2 with 
the active site of the enzyme, since PAI-2 did not affect the 
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bound uPA and prouPA towards PAI-2. THP-1 
cells were preincubated  for I h at 4°C in the ab- 
sence (-) or in the presence of either uPA or 
prouPA,  as indicated.  The cells were washed 
and further incubated with (+) or without (-) 
PAI-2 (2"x  10  -g M) for  1 h  at 4°C. Finally, 
the cells were washed again and embedded in 
a mixture of agar, casein, and plasminogen  (A) 
or  in the  same  mixture supplemented with 
PAI-2 (2  x  10  -s M)  (B).  PAI-2 is a highly 
specific inhibitor  of PAs and does not react with 
plasmin (Kruithof et al.,  1986).  Photographs 
were  taken  after  40  h  at  37°C;  proteolytic 
plaques appear as dark circles in a clear back- 
ground. No plaques were seen in parallel incu- 
bations performed  in the absence of plasmino- 
gen, confirming that lysis of the substrate was 
mediated by plasmin. 
Figure 5.  Kinetics of interaction of re- 
ceptor-bound and free uPA with PAI-2. 
(Bound uPA) THP-I  cells were  prein- 
cubated  with  ~25I-uPA for 2  h  at 4°C. 
After washing,  they were  incubated in 
the presence of PAI-2 (2 x  10  -g M) for 
0, 2, 5, 20, and 60 min at 4°C. The reac- 
tion was stopped by centrifugation  of the 
cells through an oil cushion. The cells 
were  solubilized and the samples  ana- 
lyzed by SDS-PAGE and autoradiogra- 
phy of the gel.  (Unbound uPA) A mix- 
ture of 55,000  and 33,000 Mr  125I-uPA 
containing  the same amount of radioac- 
tivity as the washed cell suspension (see 
above) was prepared.  It was handled as 
described above, except that the reaction 
with PAI-2 was stopped by adding elec- 
trophoresis sample buffer directly to the 
incubation medium. 
Figure 6. Receptor-bound uPA remains functional  at the cell 
surface. THP-1 cells were preincubated for 1 h at 4°C in the 
presence  of  ~25I-uPA; they  were  washed  and  further  in- 
cubated at 37°C for 0,  1, 2, and 4 h. The cells were then 
transferred on ice and kept for 1 h in the absence (-) or pres- 
ence (+) of PAI-2 (2  ×  10  -s M). The washed cells were 
solubilized and analyzed by SDS-PAGE followed by autora- 
diography  of the gel. 
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Figure 7. Rate of decrease in cell-associated uPA. THP-1 cells were 
incubated with either single-chain nSI-prouPA (*), two-chain ac- 
tive (A,  A), or DFP-treated  (x) ~25I-uPA for 2 h at 4°C.  After 
washing, the cells were further incubated in the absence (.,  x, ,) 
or in the presence (zx) of PAI-2 for 0, 5, 20, 60, and 120 min at 
37°C. The cells were then centrifuged through an oil cushion, and 
both  cell-associated  and  free radioactivity  were  counted.  Each 
point is the mean of  duplicate determinations; values differ by <2 % 
from the average value. 
fate of receptor-bound DFP-inactivated  ~2~I-uPA (data  not 
shown). These results suggest that when PAI-2 reacts with 
receptor-bound uPA, the fate of the enzyme/inhibitor com- 
plex is different from that of the free enzyme. 
To determine the fate of the receptor-bound complexes, 
THP-1 cells with bound ~2~I-uPA were incubated in the pres- 
ence of PAI-2 for 20 and 150 min at 37°C, and analyzed by 
SDS-PAGE and autoradiography of the gel (Fig. 8). After 20 
min, the major cell-associated radioactive band was that of 
the  95,000-Mr  uPA/PAI-2  complex.  However,  two  addi- 
tional bands, one at 70,000-M, and the other migrating with 
the electrophoretic front, were also conspicuous; these most 
likely represent degradation intermediates of the  t25I-uPA/ 
PAI-2 complex. After 150 min, only a small amount of low 
relative molecular mass  radioactive degradation  products 
could be detected; no free uPA and only very little uPA/PAI- 
2 complex remained associated with the cells. As expected 
Figure 8. Fate of receptor-bound uPA after interaction with PAI-2. 
THP-1 cells were preincubated with 55,000-Mr ~z~I-uPA for 1 h at 
4°C. The cells were then washed, incubated at 37°C in the absence 
(-) or presence (+) of PAI-2 (2  x  10  -8 M) for 20 and  150 rain 
and finally centrifuged through an oil cushion. The cells were solu- 
bilized and the samples analyzed by SDS-PAGE  and autoradiogra- 
phy of the gel. 
from the experiments reported above, in the absence of PAI-2 
the amount of cell-associated 125I-uPA decreased only slight- 
ly between 20 and 150 min of incubation; furthermore, no 
evidence was obtained for degradation of the bound active 
enzyme. 
These  results  demonstrate  that,  as  compared  to  active 
~25I-uPA,  the  125I-uPA/PAI-2 complex  is  rapidly  cleared 
from the cell surface.  Experiments in  which  the medium 
from cultures of THP-1 ceils incubated in the presence or ab- 
sence of PAI-2  was also analyzed indicate that dissociation 
of the intact t25I-uPA/PAI-2 complex from the cell surface 
was  not  significantly greater than  that  of active  ~2SI-uPA. 
The earliest detectable evidence of degradation is the forma- 
tion of a  70,000-Mr radioactive species (Fig.  8).  To deter- 
mine whether this degradation intermediate is present on the 
cell surface, or whether it is formed upon endocytosis of the 
uPA/PAI-2 complex, THP-1 cells with receptor-bound 1251- 
uPA were incubated at 37°C in the presence of PAI-2, ex- 
posed to trypsin, washed, and analyzed by SDS-PAGE and 
autoradiography of the  gel  (Fig.  9).  Both the uPA/PAI-2 
95,000-Mr  complex and  the  70,000-Mr  degradation  inter- 
mediate were removed by trypsin, indicating that they are ex- 
posed at the cell surface. By contrast, the low relative molec- 
ular  mass  radiolabeled  products  were  not  detectably 
affected; since they were not present in trypsin-treated sam- 
ples from cells incubated in the absence of PAI-2, they do 
not result from tryptic digestion of cell surface t25I-uPA, but 
must  be  intracellular,  resulting  from  degradation  of the 
uPA/PAI-2 complex after it has been endocytosed. Further 
evidence for the initial cleavage of the t25I-uPA/PAI-2 com- 
plex occurring at the cell surface was obtained in experi- 
ments  performed  at  4°C.  Formation  of  the  70,000-Mr 
degradation intermediate was also observed under these con- 
ditions, which prevent endocytosis (Fig.  6). 
Additional experiments were carried out using preformed 
'25I-uPA/PAI-2  complexes.  At  4°C,  the  complexes  were 
found to bind to THP-1 cells only slightly less efficiently  than 
active uPA;  their binding  was  prevented by excess DFP- 
inactivated 55,000-Mr uPA. By contrast, a complex formed 
between PAI-2 and 33,000-Mr ~25I-uPA did not bind to the 
cells (Fig.  10).  After binding of the preformed complexes, 
the cells were further incubated at 37°C;  at various times 
ranging from 5 to 120 min, they were collected and analyzed 
by  SDS-PAGE and  autoradiography of the gel.  The cell- 
associated radioactive 95,000-Mr complex disappeared with 
a half-time of--45 min, and degradation intermediates simi- 
lar to those illustrated in Fig. 8 were also observed; by con- 
trast, the radiolabeled 95,000-M~ complex incubated in the 
presence  of THP-1  cells  saturated  with  unlabeled  DFP- 
inactivated uPA remained stable in the medium, indicating 
that binding is required for degradation of the complex (data 
not shown).  Taken together, these results  suggest that the 
uPA/PAI-2 complex binds to THP-1 cells exclusively  through 
the A chain of the enzyme, and that at least the initial steps 
in the clearance of  uPA/PAI-2 complexes do not depend upon 
interaction of the PAI-2 moiety of the complex with a puta- 
tive PAI-2  receptor. 
Discussion 
The identification of a plasma membrane binding site spe- 
cific for uPA has led to the speculation that the enzyme acts 
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are present at the cell surface. THP-1 cells were 
preincubated  with  ~25I-uPA for  2  h  at  4°C, 
washed, and further incubated at 37°C for 0, 20, 
and 60 min in the absence (-) or presence (+) of 
PAI-2 (2 ×  10  -s M). The cells were collected and 
treated with (+) or without (-) trypsin for 10 rain 
at 20°C. The reaction was stopped by the addition 
of FBS (15%) and centrifugation of the cell sus- 
pension through an oil cushion.  Both cell-associ- 
ated and free radioactivity were counted; in each 
condition  ,~15% of the  radioactivity  remained 
cell-associated  after tryptic  digestion.  The cells 
were solubilized and analyzed by SDS-PAGE fol- 
lowed by autoradiography  of the gel. 
primarily while bound at the cell surface, to catalyze spa- 
tially restricted generation of plasmin in the context of cell 
migration and invasion.  The uPA receptor may, therefore, 
play a critical role in controlling localized extracellular pro- 
teolysis, and a more detailed understanding of its structure 
and function is relevant to a variety of physiological and patho- 
logical circumstances. The present work has revealed novel 
aspects of the cell biology of receptor-bound uPA, and there- 
by provides a sharper view of the probable functions of the 
receptor. 
Using different biochemical and morphological approaches, 
we have shown that receptor-bound uPA remains exposed at 
the cell surface with a half-life of 4-5 h. These results extend 
the observations of StoppeUi et al.  (1985)  and Bajpai and 
Baker (1985), who had reported that a large fraction of uPA 
is accessible to trypsin or acid elution 2--4 h  after binding 
to the cells.  The slow endocytosis of uPA is in contrast to 
the  rapid  internalization  of other  ligands  of cell  surface 
receptors present on the  same cells,  for instance  insulin. 
Most importantly, using the property of the active enzyme 
to react with PAI-2, we have demonstrated that essentially 
all the  ~2q-uPA that remains cell-associated even after long 
periods of incubation at 37°C is present in a functional state 
on the plasma membrane. These observations provide strong 
support to the notion that the binding of uPA to its receptor 
can serve to localize enzyme activity to the immediate envi- 
ronment of the cell. 
f°I  
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Figure 10.  Binding of 33,000 
and 55,000-Mr 12SI-uPA/PAI-2 
complexes  to  THP-1 cells. 
Cells  were  incubated  in  the 
presence of 33,000 or 55,000- 
Mr  ~:SI-uPA or of the  corre- 
sponding uPA/PAI-2  complexes 
for 2 h at 4°C without (hatched 
bars,  total binding)  or  with 
(open bars, nonspecific bind- 
ing) a  100x  molar excess  of DFP-treated  55,000-M~ unlabeled 
uPA. The cells were washed by centrifugation through an oil cush- 
ion. Both cell-associated and free radioactivity were counted. The 
mean value and range are indicated. 
The rapid redistribution of the uPA receptor in response 
to  a  chemotactic signal  provides a  mechanism to achieve 
polarized expression of a powerful proteolytic cascade to the 
leading edge of migrating cells.  This allows the highly fo- 
cused degradation of extracellular matrix components that is 
likely to be required for the migration of ceils within tissues. 
A number of studies have shown that matrix degradation can 
occur  in  a  very  localized  configuration,  suggesting  that 
membrane-associated proteases are involved (Chela  et al., 
1984;  Fairbairn  et  al.,  1985;  Kramer et  al.,  1986).  Im- 
munochemical  studies  on human fibroblasts and  fibrosar- 
coma cell cultures have demonstrated the presence of uPA 
at sites of attachment of the cells to the substratum, and its 
colocalization  with  the  cytoskeletal  component  vinculin 
(Pfll~inen  et al., 1988; H6bert and Baker, 1988). The present 
work shows that, by binding to its plasma membrane recep- 
tor, uPA can be expressed on the cell surface in a controlled 
configuration,  which  appears adequate  for the  directional 
migration of monocytes towards a chemotactic signal, uPA 
activity has been shown to be required  for the invasion of 
extracelhlar matrices by certain malignant cells (Mignatti 
et al.,  1986;  Ossowski,  1988a,b);  this  anarchic  behavior 
could be related to the inappropriate expression of receptor- 
bound uPA. 
It has previously been suggested that receptor-bound uPA 
may  be  protected  from  rapid  inhibition  by  antiproteases 
(Blasi et al.,  1987). Our results clearly show that this is not 
the case: we observed only a  slight decrease in the rate of 
uPA/PAI-2 complex formation when the enzyme was recep- 
tor-bound.  Thus,  the  receptor does not prevent uPA from 
reacting with either PAI-1 (Cubellis et al.,  1989) or PAI-2, 
and pericellular proteolysis catalyzed by bound uPA is in- 
hibited in the presence of the two PA-specific serpins. A re- 
cent paper by Kirchheimer and Remold (1989) has presented 
results that cannot easily be reconciled with our findings or 
with those of Cubellis et al. (1989): addition of PAI-1 or PAl- 
2 did not cause a marked inhibition of exogenous uPA bound 
to human monocytes; endogenous PAI-2, which is abundant 
in human monocytes (Wohlwend et al.,  1987), may have in- 
fluenced the results of these experiments, while in our case 
we have used a  monocyte-like cell line selected because it 
contains and secretes very little endogenous PAI. In any event, 
these observations should be considered in the broader con- 
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count the following findings: plasminogen binds to cells that 
also have uPA receptors (Plow et al.,  1986),  the binding of 
plasminogen accelerates the activation of bound prouPA and 
thereby plasmin formation (Ellis et al., 1989), and cell-bound 
plasmin is protected from inhibition by t~2-antiplasmin (Plow 
et al., 1986). Thus, plasmin-catalyzed cell-surface proteoly- 
sis may be resistant to inhibition by the major plasma anti- 
proteases. Regulation of plasminogen-dependent extraceUu- 
lar matrix degradation must therefore rely on the control of 
uPA synthesis and activity; it is reasonable to envision that 
PAIs, which are produced, under the influence of hormones 
and cytokines, by cells that also synthesize uPA and have uPA 
and plasminogen receptors, could play an important part in 
modulating the activity of the cell surface uPA/plasmin pro- 
teolytic system. 
In contrast to the active enzyme and to DFP-inactivated 
uPA,  the uPA/PAI-2  complex, whether formed on the uPA 
receptor or in solution, is rapidly cleared from the cell sur- 
face.  This  is  preceded  by an initial cleavage  of the cell- 
associated  complex  to  yield  a  surface-bound  70,000-3,/, 
degradation intermediate, and is followed by intracellular 
degradation.  Since a  complex formed between PAI-2 and 
33,000-Mr  uPA does not bind directly to the cell surface, 
and since the 70,000-Mr  intermediate is surface-bound, the 
receptor binding determinants in the amino-terminal region 
of the A-chain of uPA are probably not removed in this first 
cleavage. Also, because removal of the carboxy-terminal re- 
gion of the B chain of uPA (i.e., beyond the active site serine 
residue) would not suffice to cause a 25,000  D decrease in 
the apparent relative molecular mass of the complex, it fol- 
lows that the cleavage(s)  must involve the PAI-2 molecule. 
Alternatively, a change in conformation of the uPA/PAI-2 
complex could allow it to remain membrane-bound even fol- 
lowing removal of  part of the A-chain of  uPA. Further studies 
will be required to decide between these possibilities. In- 
terestingly, clearance of uPA/PAI-2  complexes does not re- 
sult in  a  rapid  freeing of cell surface uPA  receptors:  no 
significant difference in number of receptors available for 
binding was observed whether the cells had been incubated 
with or without PAI-2 for 2 h (data not shown). Thus, the 
receptor could be internalized and degraded concomitantly 
with the complexes, or the proteolytic cleavage occurring at 
the cell surface may also affect the receptor and thereby inac- 
tivate it.  Whatever: the precise mechanism for removal of 
uPA/PAI-2  complexes from the cell surface, the functional 
consequences of this reaction are the following: (a) the cell 
surface  does  not  remain  encumbered  by  PAI-2-inhibited 
uPA; (b) the uPA receptor can serve as a clearance receptor 
for uPA/PAI-2 complexes, whether these are formed on the 
cell surface or in solution. Similar results have recently been 
obtained concerning the  fate of uPA/PAI-1  complexes on 
U937 cells (Cubellis et al.,  1990),  thus strengthening the 
proposed role of the uPA receptor in the clearance of serpin- 
inactivated uPA. 
The present studies were performed on cells  from the 
monocyte-macrophage lineage. The colocalization of recep- 
tor-bound uPA with the cytoskeleton-associated protein vin- 
culin at cell attachment sites of fibroblasts (H6bert and Baker, 
1988) suggests that these cells also can polarize uPA recep- 
tors to discrete domains of their plasma membrane. It will 
be of interest to determine whether the uPA receptors on 
cells other than monocytes-macrophages can function in the 
clearance of uPA/PAI-2  complexes. In any event, together 
with the previously reported modulations of the number and 
affinity of uPA receptors (Stoppelli et al., 1985;  Estreicher 
et al., 1989;  Picone et al.,  1989),  our results further illus- 
trate the dynamic nature of uPA/receptor interaction. 
A number of possible physiological functions have been 
proposed for the uPA receptor. Specific binding of the en- 
zyme has been shown to be required for uPA-dependent inva- 
sion of the  extracellular matrix by  malignant cells  (Os- 
sowski, 1988b),  for uPA-induced chemotaxis of endothelial 
cells (Fibbi  et al.,  1988)  and for uPA stimulation of cell 
proliferation (Kirchheimer et al., 1987, 1989).  The experi- 
ments reported here provide strong support in favor of a role 
of the uPA receptor in focusing uPA activity to the leading 
front of migrating cells, and demonstrate that it also acts as 
a  clearance receptor  for uPA/PAI-2  complexes.  The uPA 
receptor appears to be a key determinant in the control of 
uPA-catalyzed proteolysis. 
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